ArticleHemaSphere2025
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study.
Abstract read
In one paragraph
Article in HemaSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis.Journal of hematology & oncology · 2026Pooled it
- Non-ICANS neurologic toxicity after BCMA CAR-T therapy: a systematic review and meta-analysis of 4630 patients with multiple myeloma.Blood advances · 2026Pooled it
- Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review.Annals of hematology · 2026Pooled it
- CART-immune-related adverse events after BCMA CAR-T therapy.Molecular therapy. Oncology · 2026Article
- Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.Blood cancer discovery · 2026Article
- Long-term safety and efficacy of BCMA-directed CAR T-cell therapies in multiple myeloma: comparative insights from Cilta-cel, Ide-cel, Anito-cel, and FCARH143.Translational cancer research · 2026Article
- Real-world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma: A single-centre experience.British journal of haematology · 2026Article
- Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.Bone marrow transplantation · 2026Article
- Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy.Journal of comparative effectiveness research · 2026Observational
- Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.Journal of hematology & oncology · 2026Article
- Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT.Bone marrow transplantation · 2026Article
- Pharmacokinetics of CAR T cells in multiple myeloma - the good, the bad, and the ugly.Leukemia · 2026Review
- FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA.Advances in therapy · 2026Article
- MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel.Leukemia · 2026Article
- Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myeloma.HemaSphere · 2026Article
- CAR T-cells in multiple myeloma: the race to the start line.Bone marrow transplantation · 2026Review
- Feasibility of outpatient administration of ciltacabtagene autoleucel and reduction in healthcare utilization cost: the Vanderbilt experience.Bone marrow transplantation · 2026Article
- Role of Radiotherapy in the Era of Novel Immune-Based Treatment Strategies for Multiple Myeloma.Hematological oncology · 2026Review
- Review
- 2025 Update of Cellular Immunotherapy for Plasma Cell Disorders.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Maximilian MerzDepartment of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases Universitätsklinikum Leipzig Leipzig Germany.ORCID 0000-0002-2805-5973
Anca-Maria AlbiciKlinik für Innere Medizin II - Hämatologie, Onkologie, University Hospital Schleswig-Holstein Kiel Kiel University Kiel Germany.
Bastian von TresckowDepartment of Haematology and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (DKTK partner site Essen), University Hospital Essen University of Duisburg-Essen Essen Germany.
Kristin RathjeInterdisziplinäre Klinik und Poliklinik für Stammzelltransplantation University Medical Center Hamburg-Eppendorf Hamburg Germany.
Roland FenkKlinik für Hämatologie, Onkologie und Klinische Immunologie, Heinrich Heine University University Hospital Düsseldorf Düsseldorf Germany.
Tobias HolderriedMedizinische Klinik und Poliklinik III - Innere Medizin mit den Schwerpunkten Onkologie, Hämatologie, Immunonkologie und Rheumatologie Universitätsklinikum Bonn Bonn Germany.
Fabian MüllerDepartment of Internal Medicine 5, Haematology and Oncology, University Hospital of Erlangen Friedrich-Alexander University of Erlangen-Nuremberg (FAU) Erlangen Germany.ORCID 0000-0001-5487-5839
Natalia TovarInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Hospital Clínic de Barcelona Barcelona Spain.
Aina Oliver-CáldesInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Hospital Clínic de Barcelona Barcelona Spain.
Vladan VucinicDepartment of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases Universitätsklinikum Leipzig Leipzig Germany.ORCID 0000-0002-8398-285X
Soraya KharboutliDepartment of Internal Medicine 5, Haematology and Oncology, University Hospital of Erlangen Friedrich-Alexander University of Erlangen-Nuremberg (FAU) Erlangen Germany.
Ben-Niklas BärmannKlinik für Hämatologie, Onkologie und Klinische Immunologie, Heinrich Heine University University Hospital Düsseldorf Düsseldorf Germany.
Francis AyukInterdisziplinäre Klinik und Poliklinik für Stammzelltransplantation University Medical Center Hamburg-Eppendorf Hamburg Germany.
Uwe PlatzbeckerDepartment of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases Universitätsklinikum Leipzig Leipzig Germany.
Friedrich StölzelKlinik für Innere Medizin II - Hämatologie, Onkologie, University Hospital Schleswig-Holstein Kiel Kiel University Kiel Germany.
Nathalie SchubKlinik für Innere Medizin II - Hämatologie, Onkologie, University Hospital Schleswig-Holstein Kiel Kiel University Kiel Germany.
Friederike SchmitzMedizinische Klinik und Poliklinik III - Innere Medizin mit den Schwerpunkten Onkologie, Hämatologie, Immunonkologie und Rheumatologie Universitätsklinikum Bonn Bonn Germany.
David FandreiDepartment of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases Universitätsklinikum Leipzig Leipzig Germany.
Patrick BornDepartment of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases Universitätsklinikum Leipzig Leipzig Germany.
Cyrus KhandanpourKlinik für Hämatologie und Onkologie University Hospital Lübeck Lübeck Germany.
Christine HanounDepartment of Haematology and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (DKTK partner site Essen), University Hospital Essen University of Duisburg-Essen Essen Germany.ORCID 0000-0003-2766-1696
Keven HörsterDepartment of Haematology and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (DKTK partner site Essen), University Hospital Essen University of Duisburg-Essen Essen Germany.
Marcel TeichertDepartment of Haematology and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (DKTK partner site Essen), University Hospital Essen University of Duisburg-Essen Essen Germany.
Barbara JekerUniversitätsklinik für Medizinische Onkologie, Inselspital Bern University Hospital, Bern Bern Schweiz.
Michele HoffmannUniversitätsklinik für Medizinische Onkologie, Inselspital Bern University Hospital, Bern Bern Schweiz.
Nicolaus KrögerInterdisziplinäre Klinik und Poliklinik für Stammzelltransplantation University Medical Center Hamburg-Eppendorf Hamburg Germany.
Carlos Fernández de LarreaInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Hospital Clínic de Barcelona Barcelona Spain.ORCID 0000-0003-4930-9255
Thomas PabstUniversitätsklinik für Medizinische Onkologie, Inselspital Bern University Hospital, Bern Bern Schweiz.
Nico GagelmannInterdisziplinäre Klinik und Poliklinik für Stammzelltransplantation University Medical Center Hamburg-Eppendorf Hamburg Germany.ORCID https://orcid.org/0000-0002-0891-1744
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM), but direct comparisons are lacking. Leveraging an international multicenter RRMM cohort, we compared the outcome of ide-cel (
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.